In a phase 2b clinical trial, Beckley Psytech has started treating the first subject for BPL-003, an intranasal synthetic formulation of the psychedelic chemical 5-MeO-DMT intended for patients with treatment-resistant depression. With FDA clearance for investigational new medication status in February, this groundbreaking research represents the biggest controlled examination into the potential of 5-MeO-DMT, involving 40 locations throughout Australia, Europe, and the US.
Get ready for Deep Stories’ CannaLand! Arizona’s premier one-day cannabis festival begins 11 a.m. on…
They sit in circles, eyes gleaming with hope as they declare, "If I could only…
In a move that surprised absolutely no one who's been paying attention, the White House…
The NBA champion and New York Knick will premier his new flower brand at Torches…
By: LMC Legacy to licensed is the motto for authentic New York brands entering the…
Vlad Bautista began his cannabis empire in Harlem's Sugar Hill. Nearly 30 years later, his…